Atlantic Trust Group LLC maintained its position in shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 12,591 shares of the company’s stock at the end of the second quarter. Atlantic Trust Group LLC owned about 0.06% of Reata Pharmaceuticals worth $398,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Teachers Advisors LLC raised its holdings in shares of Reata Pharmaceuticals by 12.8% during the 4th quarter. Teachers Advisors LLC now owns 10,116 shares of the company’s stock worth $221,000 after acquiring an additional 1,148 shares during the period. Russell Investments Group Ltd. purchased a new position in shares of Reata Pharmaceuticals during the 2nd quarter worth $254,000. Rhumbline Advisers purchased a new position in shares of Reata Pharmaceuticals during the 2nd quarter worth $303,000. Fifth Third Bancorp purchased a new position in shares of Reata Pharmaceuticals during the 1st quarter worth $395,000. Finally, Alps Advisors Inc. purchased a new position in shares of Reata Pharmaceuticals during the 2nd quarter worth $400,000. Institutional investors and hedge funds own 21.85% of the company’s stock.

Shares of Reata Pharmaceuticals, Inc. (RETA) opened at 29.77 on Wednesday. Reata Pharmaceuticals, Inc. has a one year low of $18.51 and a one year high of $41.60. The stock’s market capitalization is $777.09 million. The company has a 50-day moving average of $28.88 and a 200 day moving average of $26.77.

Several research firms have recently commented on RETA. Robert W. Baird reiterated an “outperform” rating and set a $47.00 price target (up previously from $43.00) on shares of Reata Pharmaceuticals in a report on Tuesday, July 25th. Stifel Nicolaus reiterated a “buy” rating and set a $50.00 price target (up previously from $38.00) on shares of Reata Pharmaceuticals in a report on Tuesday, July 25th. Citigroup Inc. reiterated a “buy” rating and set a $87.00 price target (up previously from $39.00) on shares of Reata Pharmaceuticals in a report on Tuesday, July 25th. Ladenburg Thalmann Financial Services reiterated a “buy” rating and set a $61.00 price target (up previously from $55.00) on shares of Reata Pharmaceuticals in a report on Wednesday, July 26th. Finally, Zacks Investment Research lowered Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, July 18th. Two investment analysts have rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $52.86.

WARNING: This report was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/09/13/atlantic-trust-group-llc-has-398000-stake-in-reata-pharmaceuticals-inc-reta.html.

In related news, Director James Edward Bass acquired 8,064 shares of the firm’s stock in a transaction that occurred on Tuesday, August 1st. The shares were acquired at an average price of $31.00 per share, with a total value of $249,984.00. Following the completion of the purchase, the director now directly owns 67,411 shares in the company, valued at $2,089,741. The purchase was disclosed in a document filed with the SEC, which is available through this link. 62.40% of the stock is owned by company insiders.

Reata Pharmaceuticals Company Profile

Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.

Institutional Ownership by Quarter for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Stock Ratings for Reata Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.